Case TS-4685851219 Nov 2026Mixed

Beauty

“A kojic acid body lotion can be used to treat dark underarms caused by hyperpigmentation." (Post framing: "I'm willing to go out on a limb and say you could probably go ahead and use this under the arms for dark underarms... this particular body lotion with kojic acid is very gentle and should be pretty well tolerated in the skin…”

Plain restatementA leave-on body lotion containing kojic acid can be applied to the underarm to reduce darkening when that darkening is post-inflammatory or melanin-driven hyperpigmentation rather than acanthosis nigricans. Three sub-assertions travel with it: (a) kojic acid reduces hyperpigmentation; (b) a kojic acid lotion is well tolerated in the axillary skin fold; (c) acanthosis nigricans is a sign of insulin resistance and kojic acid does not treat it.

Partially accurate but misleadingConfidence Medium
What this verdict means →

General information only - not medical or dermatological advice.

This post suggests a kojic acid body lotion can be used on dark underarms when the cause is hyperpigmentation. Kojic acid does have published clinical evidence as a pigment-reducing ingredient, but that evidence comes almost entirely from the face, usually at 1 to 4 percent and often combined with glycolic acid. A systematic review published in August 2025 that searched four medical databases for underarm hyperpigmentation treatments found ten studies, and kojic acid was not among the ingredients tested at that site. The post also describes the lotion as gentle and well tolerated in skin folds, and no study of kojic acid tolerability in skin folds was found, while human patch testing has recorded kojic acid as a substance some people become allergic to. The post's point that acanthosis nigricans is a different condition from hyperpigmentation is supported, and acanthosis nigricans is associated with insulin resistance in observational research, though that research shows an association rather than proving cause. One further detail worth knowing is that in the European Union kojic acid is restricted to a maximum of 1 percent and only in face and hand products, so underarm use sits outside that category there; the claim named no country and rules differ elsewhere. Anyone noticing a change in skin colour or texture in the underarm or neck is best served by raising it with a doctor, since the cause determines whether a topical product is relevant at all. General information only, not medical or dermatological advice.

The drift / as claimed vs as evidenced

A [drifted from the evidence:] kojic acid body lotion can be [drifted from the evidence:] used to treat dark underarms caused by hyperpigmentation." (Post framing: "I'm willing to [drifted from the evidence:] go out on a limb and say you could probably go ahead and use this under the [drifted from the evidence:] arms for dark underarms... this particular body lotion with kojic acid is [drifted from the evidence:] very gentle and should be pretty well tolerated in the skin [drifted from the evidence:] folds... Kojic acid will not treat acanthosis nigricans... [acanthosis nigricans] is a [drifted from the evidence:] warning sign of insulin resistance.")


A [added by the neutral restatement:] leave-on body lotion [added by the neutral restatement:] containing kojic acid can be [added by the neutral restatement:] applied to the [added by the neutral restatement:] underarm to reduce darkening when that darkening is post-inflammatory or melanin-driven hyperpigmentation rather than acanthosis nigricans. Three sub-assertions travel with [added by the neutral restatement:] it: (a) kojic acid [added by the neutral restatement:] reduces hyperpigmentation; (b) a kojic acid lotion is well tolerated in the [added by the neutral restatement:] axillary skin [added by the neutral restatement:] fold; (c) acanthosis nigricans is a sign of insulin resistance [added by the neutral restatement:] and kojic acid does not treat it.

Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.

The trace / claim to source

restriction as ban
Tertiary sourcetrade regulatory consultancies, context only
SGS and MedEnvoy regulatory summaries of Commission Regulation (EU) 2024/996 adding kojic acid to Annex III
Secondary sourcepeer-reviewed
Phasha et al., "Review on the Use of Kojic Acid, A Skin-Lightening Ingredient," Cosmetics 2022;9(3):64
Secondary sourceindustry-funded US assessment body of record
CIR Expert Panel strategy memo on kojic acid
Primary sourceEU assessment body of record
SCCS Opinion on Kojic Acid, SCCS/1637/21, final version and corrigendum
Primary sourcepeer-reviewed
Vahabi et al., "Axillary Hyperpigmentation Treatment: A Systematic Review of the Literature," J Cosmet Dermatol 2025;24(8):e70418
Primary sourcepeer-reviewed
Nakagawa & Kawai, "Contact allergy to kojic acid in skin care products," Contact Dermatitis 1995
Primary sourcepeer-reviewed
Deo et al., "Kojic acid vis-a-vis its combinations with hydroquinone and betamethasone valerate in melasma," Indian J Dermatol 2013;58(4):281-285, as reported in a JCAD systematic review
Primary sourcepeer-reviewed
Castanedo-Cazares et al., "Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation," CCID (NCT01542138)
Primary sourcepeer-reviewed
"Assessing the efficacy and safety profiles of 0.025% tretinoin in treating axillary hyperpigmentation with acanthosis nigricans," Arch Dermatol Res 2025;317(1):297
Primary sourcepeer-reviewed
Acanthosis nigricans as a marker of insulin resistance: multiple observational studies, e.g. PLoS One 2020 (Mexican American children), Diabetes Care 2002
● Primary source found
What is true
  • Kojic acid has published clinical evidence as a pigment-reducing ingredient. A 1.0% formulation improved several facial hyperpigmentary conditions in a clinical trial, and 2% kojic acid combined with 5% glycolic acid performed comparably to a hydroquinone combination in about half of 39 patients in a split-face study of facial hyperpigmentation.
  • The distinction the post draws between hyperpigmentation and acanthosis nigricans is a real clinical distinction. Acanthosis nigricans is described in the literature as velvety thickening of the epidermis affecting the axillae, posterior neck, flexural surfaces and umbilicus, which is a different process from excess melanin deposition.
  • Acanthosis nigricans is associated with obesity and insulin resistance in observational studies and has been used as a screening marker for type 2 diabetes risk, particularly in children and adolescents. This is an association found in observational data; causation is not established by those study designs.
  • No study was found testing kojic acid in acanthosis nigricans, so the post's statement that kojic acid will not treat it is consistent with the absence of any evidence that it does, and consistent with the mismatch between the ingredient's tyrosinase-inhibiting mechanism and a condition of epidermal thickening.
  • The post does flag that the response depends on the underlying cause, and it presents the underarm use as an extrapolation rather than an established indication.
What is misleading
  • The claim says a kojic acid lotion can treat dark underarms. The strongest source on this exact question, a systematic review published in August 2025 that searched four databases to June 2025, found ten studies of axillary hyperpigmentation treatment and kojic acid was not among the topical agents studied. The evidence for kojic acid comes from the face, mostly from melasma, and transferring it to the axilla is an assumption the claim does not flag.
  • The statement that the lotion is very gentle and should be well tolerated in the skin folds is offered as a property of the product. No study of kojic acid tolerability in intertriginous skin was found. Against this, human patch testing records kojic acid as a sensitiser: in a 1995 series, five of eight people who had used kojic acid products reacted to it and developed facial dermatitis one to twelve months after starting use, while 212 never-users all tested negative. The SCCS cites positive reactions down to 0.5% in a case report. Whether that risk is higher or lower in a shaved, occluded fold has not been measured.
  • The underarm sits outside the use conditions the EU assessment and Annex III entry cover. In the EU, as of the 2024/996 amendment, kojic acid is restricted to a maximum of 1% in face and hand products, so a body lotion applied to the underarm is not within that permitted category. This is a restriction with a concentration cap and a product-category limit, not a ban, and it applies in the EU only. No jurisdiction was named in the claim.
  • The kojic acid concentration in the lotion is never stated. The published benefits sit at 1% to 4%, and much of the better data comes from combinations with glycolic acid, so a reader cannot tell whether the product discussed is at a studied strength or whether any effect would be attributable to kojic acid at all.
  • The post contrasts kojic acid favourably against glycolic acid for the underarm. An alpha hydroxy acid is among the agents the 2025 axillary review identified as having been studied at that site, whereas kojic acid is not. The site-specific evidence base runs the opposite way to the comparison implied.
What is uncertain
  • Whether kojic acid reduces axillary hyperpigmentation at any concentration is an open question. No trial at that site was located, so the direction and size of any effect are unknown.
  • Whether kojic acid tolerance in the axilla differs from tolerance on the face is unmeasured. Occlusion and shaving plausibly change absorption and irritation, but no study has tested it.
  • The exact final SCCS safe-use figure is unsettled in the sources available. The official document extract and the later Annex III entry both point to 1%, while one regulatory news summary reports 0.7%, and the corrigendum history explains part but not all of the discrepancy.
  • Whether kojic acid has any effect on acanthosis nigricans has not been tested in either direction. The post's negative statement is reasonable on mechanism but is not backed by a trial.
  • The relative contribution of kojic acid, as opposed to the glycolic acid or hydroquinone it was combined with, is not isolated in the strongest facial studies.
  • Funding sources for the kojic acid efficacy trials were not disclosed in the retrieved records.
Evidence summary

Kojic acid has a real but modest clinical record as a pigment-reducing ingredient, and that record is almost entirely facial. A 2022 peer-reviewed review describes a clinical trial in which a 1.0% kojic acid formulation improved freckles, age spots, post-inflammatory hyperpigmentation and melasma, and a split-face study in 39 patients with facial hyperpigmentation in which 2% kojic acid plus 5% glycolic acid performed comparably to 2% hydroquinone plus 5% glycolic acid in about half of patients. A randomised single-blind comparative study by Deo and colleagues in melasma found hydroquinone overall superior to kojic acid cream in lightening at week 12. A 2023 Polish study using 3% kojic acid and hyperspectral imaging was explicitly described by its authors as preliminary and was conducted on facial skin. For the underarm specifically, the strongest available source is the August 2025 systematic review of axillary hyperpigmentation treatment, which searched PubMed, Scopus, Web of Science and Embase to 1 June 2025 and retrieved ten studies. The topical agents it identified as studied in the axilla were niacinamide, desonide, Cyperus rotundus essential oil, an alpha hydroxy acid, hydroquinone, Citrus sinensis extract and Perilla frutescens leaf extract. Kojic acid does not appear in that list. No trial of kojic acid at the axilla, and no trial of a kojic acid body lotion in any body region, was located. On tolerability in the fold, the SCCS opinion documents kojic acid's sensitising potential, citing patch testing in 220 women including five kojic-acid-sensitive patients, strong positive confirmatory reactions at 1% and 3%, and a case report of positive reactions at 0.5%, 1% and 3%. The underlying 1995 Nakagawa and Kawai series found that five of eight patients who had used kojic acid products reacted to kojic acid, with facial dermatitis developing one to twelve months after starting use, while 212 patients who had never used such products all tested negative. The SCCS exposure assessment was built on face and hand leave-on creams, not on occluded intertriginous skin. On acanthosis nigricans, the observational literature consistently treats it as a cutaneous marker associated with obesity and insulin resistance, used as a screening signal for type 2 diabetes risk, particularly in children and adolescents. Separately, a 2025 randomised intra-individual split-side study found 0.025% tretinoin improved axillary hyperpigmentation with acanthosis nigricans, with pigmentation partially returning after treatment stopped. No study testing kojic acid in acanthosis nigricans was found.

Complete reasoning
Kojic acid is a genuine pigment-reducing ingredient with modest clinical evidence, so this is not a fabricated or empty claim, which rules out False and Unverified. But the claim is site-specific, and the best source on that site, a 2025 systematic review of axillary hyperpigmentation treatment, found no kojic acid study among the ten it retrieved, so the claim rests on transferring facial melasma data to an occluded, frequently shaved fold without saying so. The accompanying assertion that the lotion is gentle and well tolerated in skin folds is presented as a product property while the human record documents kojic acid as a sensitiser and no fold-specific tolerability study exists. Mostly accurate was considered and rejected because the missing site evidence and the untested tolerability assertion are not minor simplifications, they are the whole substance of the claim; Inconclusive was considered and rejected because the evidence is not conflicting, it is clearly absent at the site in question while present elsewhere, which is a framing problem rather than an evidentiary standoff. Confidence is capped at Medium because the product is unnamed and its kojic acid concentration is unknown, which is a safety-relevant gap, and because the regulatory element names no jurisdiction.
Use this case

The reply is formatted for pasting into the thread where the claim is circulating.

Similar cases on record

Partially accurate but misleading: A leave-on body lotion containing kojic acid can be applied to the underarm to reduce dark… | TrueSeeker